Arrowhead Pharmaceuticals (ARWR) EBITDA (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly EBITDA came in at -$141.3 million in Q1 2026, down 137.06% YoY from $381.2 million in Q1 2025, and down 446.15% on a QoQ basis from $40.8 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) EBITDA (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of EBITDA data on file, last reported at -$141.3 million in Q1 2026.
- Quarterly EBITDA fell 137.06% year-over-year to -$141.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$221.9 million (down 87.17% YoY) and the FY2025 annual result came in at $98.3 million, up 116.36% from the prior year.
- EBITDA eased to -$141.3 million in Q1 2026, from $40.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $381.2 million in Q1 2025 to a low of -$176.1 million in Q2 2024.
- A 5-year average of -$54.3 million and a median of -$102.7 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA sank 362.0% — and 2025, when it soared 402.08%.
- Tracing ARWR's EBITDA over 5 years: stood at -$42.1 million in 2022, then tumbled by 224.07% to -$136.5 million in 2023, then fell by 18.21% to -$161.4 million in 2024, then jumped by 125.28% to $40.8 million in 2025, then plunged by 446.15% to -$141.3 million in 2026.
- The last three EBITDA figures came in at -$141.3 million (Q1 2026), $40.8 million (Q4 2025), and $44.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -170.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -170.09 Mn |
| Mar 31, 2026 | -141.26 Mn |
| Dec 31, 2025 | 40.81 Mn |
| Sep 30, 2025 | 44.11 Mn |
| Jun 30, 2025 | -165.55 Mn |
| Mar 31, 2025 | 381.20 Mn |
| Dec 31, 2024 | -161.41 Mn |
| Sep 30, 2024 | -162.20 Mn |
| Jun 30, 2024 | -176.14 Mn |
| Mar 31, 2024 | -126.19 Mn |
| Dec 31, 2023 | -136.55 Mn |
| Sep 30, 2023 | -108.33 Mn |
| Jun 30, 2023 | -102.70 Mn |
| Mar 31, 2023 | 48.17 Mn |
| Dec 31, 2022 | -42.13 Mn |
| Sep 30, 2022 | -83.83 Mn |
| Jun 30, 2022 | -72.91 Mn |
| Mar 31, 2022 | 41.55 Mn |
| Dec 31, 2021 | -63.32 Mn |
| Sep 30, 2021 | -64.88 Mn |